{"title":"Clinical and Patient-Reported Outcomes After Mix-and-Match Implantation of a Trifocal and Non-Diffractive Extended Depth of Focus IOL.","authors":"Irene S Zhou, Dagny C Zhu","doi":"10.2147/OPTH.S533091","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate cataract surgery outcomes following mix-and-match implantation of a trifocal and extended-depth-of-focus (EDOF) intraocular lens (IOL).</p><p><strong>Setting: </strong>Single center, private practice.</p><p><strong>Design: </strong>Single arm, non-interventional, ambispective study.</p><p><strong>Methods: </strong>Patients who underwent femtosecond-laser assisted cataract surgery with mix-and-match implantation of the Clareon PanOptix trifocal IOL in the non-dominant eye and Clareon Vivity EDOF IOL in the dominant eye from September 2022 to November 2023 were reviewed. Only healthy eyes with postoperative absolute spherical equivalent (SE) ≤ 0.50 diopters (D) and cylinder ≤ 0.75 D were included. At 3 months postoperatively, binocular corrected and uncorrected visual acuity at distance (CDVA and UDVA), intermediate (DCIVA and UIVA), and near (DCNVA and UNVA) along with patient-reported outcomes (QUVID and IOLSAT questionnaires) were assessed.</p><p><strong>Results: </strong>100 eyes of 50 patients were included. Postoperatively, the mean binocular CDVA and UDVA was -0.08 ± 0.05 logMAR and -0.06 ± 0.05 logMAR, respectively. Overall, 100%, 98%, and 90% of patients achieved binocular UDVA, UIVA, and UNVA of 20/25 or better, respectively. Eighty-four percent of patients reported complete spectacle independence. Few patients were \"bothered very much\" by haloes, glare, or starbursts (0-4%). No patients reported dissatisfaction with their vision. Overall, 94% and 92% of patients would elect the same IOLs and recommend the same procedure to friends and family, respectively.</p><p><strong>Conclusion: </strong>Mix-and-match implantation of the Clareon PanOptix and Vivity IOLs yields good patient satisfaction potentially by combining the advantages of each lens resulting in a high degree of satisfaction and low rates of visual disturbances.</p>","PeriodicalId":93945,"journal":{"name":"Clinical ophthalmology (Auckland, N.Z.)","volume":"19 ","pages":"2625-2635"},"PeriodicalIF":0.0000,"publicationDate":"2025-08-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12345935/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical ophthalmology (Auckland, N.Z.)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/OPTH.S533091","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose: To evaluate cataract surgery outcomes following mix-and-match implantation of a trifocal and extended-depth-of-focus (EDOF) intraocular lens (IOL).
Setting: Single center, private practice.
Design: Single arm, non-interventional, ambispective study.
Methods: Patients who underwent femtosecond-laser assisted cataract surgery with mix-and-match implantation of the Clareon PanOptix trifocal IOL in the non-dominant eye and Clareon Vivity EDOF IOL in the dominant eye from September 2022 to November 2023 were reviewed. Only healthy eyes with postoperative absolute spherical equivalent (SE) ≤ 0.50 diopters (D) and cylinder ≤ 0.75 D were included. At 3 months postoperatively, binocular corrected and uncorrected visual acuity at distance (CDVA and UDVA), intermediate (DCIVA and UIVA), and near (DCNVA and UNVA) along with patient-reported outcomes (QUVID and IOLSAT questionnaires) were assessed.
Results: 100 eyes of 50 patients were included. Postoperatively, the mean binocular CDVA and UDVA was -0.08 ± 0.05 logMAR and -0.06 ± 0.05 logMAR, respectively. Overall, 100%, 98%, and 90% of patients achieved binocular UDVA, UIVA, and UNVA of 20/25 or better, respectively. Eighty-four percent of patients reported complete spectacle independence. Few patients were "bothered very much" by haloes, glare, or starbursts (0-4%). No patients reported dissatisfaction with their vision. Overall, 94% and 92% of patients would elect the same IOLs and recommend the same procedure to friends and family, respectively.
Conclusion: Mix-and-match implantation of the Clareon PanOptix and Vivity IOLs yields good patient satisfaction potentially by combining the advantages of each lens resulting in a high degree of satisfaction and low rates of visual disturbances.